Alivus Life Sciences [GLS] vs Granules India [GRANULES] Detailed Stock Comparison
Alivus Life Sciences
NSE
Loading...
Granules India
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Alivus Life Sciences wins in 9 metrics, Granules India wins in 10 metrics, with 0 ties. Granules India appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Alivus Life Sciences | Granules India | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 31.45 | 23.65 | Granules India |
| Price-to-Book Ratio | 5.23 | 3.05 | Granules India |
| Debt-to-Equity Ratio | 0.63 | 39.15 | Alivus Life Sciences |
| PEG Ratio | 22.31 | -1.43 | Granules India |
| EV/EBITDA | 21.33 | 13.68 | Granules India |
| Profit Margin (TTM) | 19.21% | 10.63% | Alivus Life Sciences |
| Operating Margin (TTM) | 23.53% | 14.70% | Alivus Life Sciences |
| EBITDA Margin (TTM) | 23.53% | 14.70% | Alivus Life Sciences |
| Return on Equity | 17.18% | 13.50% | Alivus Life Sciences |
| Return on Assets (TTM) | 11.43% | 8.02% | Alivus Life Sciences |
| Free Cash Flow (TTM) | $2.85B | $2.95B | Granules India |
| Dividend Yield | N/A | 0.30% | N/A |
| 1-Year Return | -10.54% | -34.93% | Alivus Life Sciences |
| Price-to-Sales Ratio (TTM) | 6.03 | 2.51 | Granules India |
| Enterprise Value | $128.55B | $123.73B | Alivus Life Sciences |
| EV/Revenue Ratio | 5.83 | 2.74 | Granules India |
| Gross Profit Margin (TTM) | 55.55% | 64.84% | Granules India |
| Revenue per Share (TTM) | $180 | $186 | Granules India |
| Earnings per Share (Diluted) | $34.48 | $19.77 | Alivus Life Sciences |
| Beta (Stock Volatility) | 0.16 | -0.13 | Granules India |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Alivus Life Sciences vs Granules India Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Alivus Life Sciences | 0.58% | -2.95% | -7.86% | -12.05% | 6.42% | -7.52% |
| Granules India | 5.35% | 1.14% | 0.87% | -10.56% | 1.18% | -21.79% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Alivus Life Sciences | -10.54% | 114.19% | 25.81% | 25.81% | 25.81% | 25.81% |
| Granules India | -34.93% | 53.12% | 34.79% | 300.21% | 4,865.46% | 3,938.46% |
Performance & Financial Health Analysis: Alivus Life Sciences vs Granules India
| Metric | GLS | GRANULES |
|---|---|---|
| Market Information | ||
| Market Cap | ₹133.05B | ₹113.46B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 62,523 | 1,649,900 |
| 90 Day Avg. Volume | 105,168 | 1,266,157 |
| Last Close | ₹947.20 | ₹492.25 |
| 52 Week Range | ₹850.00 - ₹1,335.10 | ₹422.00 - ₹721.00 |
| % from 52W High | -29.05% | -31.73% |
| All-Time High | ₹1,335.10 (Sep 16, 2024) | ₹721.00 (Aug 26, 2024) |
| % from All-Time High | -29.05% | -31.73% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.15% | 0.03% |
| Quarterly Earnings Growth | -0.20% | -0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.19% | 0.11% |
| Operating Margin (TTM) | 0.24% | 0.15% |
| Return on Equity (TTM) | 0.17% | 0.14% |
| Debt to Equity (MRQ) | 0.63 | 39.15 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹207.20 | ₹153.19 |
| Cash per Share (MRQ) | ₹36.43 | ₹19.34 |
| Operating Cash Flow (TTM) | ₹4.17B | ₹7.56B |
| Levered Free Cash Flow (TTM) | ₹2.01B | ₹5.02B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.30% |
| Last 12-Month Dividend | ₹0.00 | ₹1.50 |
Valuation & Enterprise Metrics Analysis: Alivus Life Sciences vs Granules India
| Metric | GLS | GRANULES |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 31.45 | 23.65 |
| Forward P/E | 22.31 | 16.28 |
| PEG Ratio | 22.31 | -1.43 |
| Price to Sales (TTM) | 6.03 | 2.51 |
| Price to Book (MRQ) | 5.23 | 3.05 |
| Market Capitalization | ||
| Market Capitalization | ₹133.05B | ₹113.46B |
| Enterprise Value | ₹128.55B | ₹123.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.83 | 2.74 |
| Enterprise to EBITDA | 21.33 | 13.68 |
| Risk & Other Metrics | ||
| Beta | 0.16 | -0.13 |
| Book Value per Share (MRQ) | ₹207.20 | ₹153.19 |
Financial Statements Comparison: Alivus Life Sciences vs Granules India
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GLS | GRANULES |
|---|---|---|
| Revenue/Sales | ₹6.42B | ₹12.09B |
| Cost of Goods Sold | ₹2.85B | ₹4.25B |
| Gross Profit | ₹3.57B | ₹7.84B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.75B | ₹1.78B |
| EBITDA | ₹2.01B | ₹2.63B |
| Pre-Tax Income | ₹1.85B | ₹1.45B |
| Income Tax | ₹481.87M | ₹318.89M |
| Net Income (Profit) | ₹1.37B | ₹1.13B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GLS | GRANULES |
|---|---|---|
| Cash & Equivalents | ₹4.46B | ₹4.66B |
| Total Current Assets | ₹20.96B | ₹31.15B |
| Total Current Liabilities | ₹4.64B | ₹20.03B |
| Long-Term Debt | ₹133.80M | ₹4.71B |
| Total Shareholders Equity | ₹25.38B | ₹37.16B |
| Retained Earnings | N/A | ₹30.59B |
| Property, Plant & Equipment | ₹8.04B | ₹719.13M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GLS | GRANULES |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GLS | GRANULES |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 62,523 | 1,649,900 |
| Average Daily Volume (90 Day) | 105,168 | 1,266,157 |
| Shares Outstanding | 122.53M | 242.54M |
| Float Shares | 30.63M | 142.08M |
| % Held by Insiders | 0.76% | 0.40% |
| % Held by Institutions | 0.07% | 0.29% |
Dividend Analysis & Yield Comparison: Alivus Life Sciences vs Granules India
| Metric | GLS | GRANULES |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹1.50 |
| Last 12-Month Dividend Yield | N/A | 0.30% |
| 3-Year Avg Annual Dividend | ₹18.00 | ₹1.50 |
| 3-Year Avg Dividend Yield | 3.82% | 0.33% |
| 3-Year Total Dividends | ₹54.00 | ₹4.50 |
| Ex-Dividend Date | Oct 17, 2023 | Jul 31, 2025 |